Skip to main content

Evaluation of the Efficacy, Safety, and Tolerability of LevoCept

Not yet recruiting · Phase 3 · NCT04457076

Conditions: Contraception, Women at Risk for Pregnancy

At a glance

Research payments reported, 2025
$67,302
U.S. investigators named
8
Sites paid
8
Planned or actual enrollment
1,525

About the trial

Sponsor
Sebela Women's Health Inc. (with PRA Health Sciences)
Tested
LevoCept (drug)
Dates
Started 2026-06-01; completion 2032-06-01
Results posted
Not yet

To assess the contraceptive efficacy (prevention of pregnancy) of LevoCept

From ClinicalTrials.gov, last updated 2025-05-22. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sebela Women's Health Inc. reported $67,302 in research payments for this study in 2025 (12 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.